These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9061206)

  • 1. Discovery of OT4003, a novel, potent, and orally active cys-LT1 receptor antagonist.
    Tvaermose-Nielsen O; Rachlin S; Dannacher H; Björkling F; Kirstein D; Bramm E; Nielsen CK; Mortensen JT; Binderup L
    Bioorg Med Chem; 1997 Feb; 5(2):415-27. PubMed ID: 9061206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist.
    Jones TR; Labelle M; Belley M; Champion E; Charette L; Evans J; Ford-Hutchinson AW; Gauthier JY; Lord A; Masson P
    Can J Physiol Pharmacol; 1995 Feb; 73(2):191-201. PubMed ID: 7621356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationships of carboxyflavones as structurally rigid CysLT1 (LTD4) receptor antagonists.
    Zwaagstra ME; Timmerman H; van de Stolpe AC; de Kanter FJ; Tamura M; Wada Y; Zhang MQ
    J Med Chem; 1998 Apr; 41(9):1428-38. PubMed ID: 9554876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a novel series of styrylquinoline compounds as high-affinity leukotriene D4 receptor antagonists: synthetic and structure-activity studies leading to the discovery of (+-)-3-[[[3-[2-(7-chloro-2-quinolinyl)-(E)-ethenyl]phenyl][[3- (dimethylamino)-3-oxopropyl]thio]methyl]thio]propionic acid.
    Zamboni R; Belley M; Champion E; Charette L; DeHaven R; Frenette R; Gauthier JY; Jones TR; Leger S; Masson P
    J Med Chem; 1992 Oct; 35(21):3832-44. PubMed ID: 1331447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist.
    Jones TR; Zamboni R; Belley M; Champion E; Charette L; Ford-Hutchinson AW; Frenette R; Gauthier JY; Leger S; Masson P
    Can J Physiol Pharmacol; 1989 Jan; 67(1):17-28. PubMed ID: 2540892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of a novel series of (quinolin-2-ylmethoxy)phenyl-containing compounds as high-affinity leukotriene receptor antagonists. 3. Structural variation of the acidic side chain to give antagonists of enhanced potency.
    Galemmo RA; Johnson WH; Learn KS; Lee TD; Huang FC; Campbell HF; Youssefyeh R; O'Rourke SV; Schuessler G; Sweeney DM
    J Med Chem; 1990 Oct; 33(10):2828-41. PubMed ID: 2170649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological profile of CR3465, a new leukotriene CysLT1 receptor antagonist with broad anti-inflammatory activity.
    Ferrari F; Mennuni L; Caselli G; Zanelli T; Makovec F
    Eur J Pharmacol; 2004 Nov; 504(3):223-33. PubMed ID: 15541426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereospecific synthesis, assignment of absolute configuration, and biological activity of the enantiomers of 3-[[[3-[2-(7-chloroquinolin-2-yl)-(E)-ethenyl]phenyl] [[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]propionic acid, a potent and specific leukotriene D4 receptor antagonist.
    Gauthier JY; Jones T; Champion E; Charette L; Dehaven R; Ford-Hutchinson AW; Hoogsteen K; Lord A; Masson P; Piechuta H
    J Med Chem; 1990 Oct; 33(10):2841-5. PubMed ID: 2170650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-[(arylmethoxy)phenyl] carboxylic acids, hydroxamic acids, tetrazoles, and sulfonyl carboxamides. Potent orally active leukotriene D4 antagonists of novel structure.
    Musser JH; Kreft AF; Bender RH; Kubrak DM; Grimes D; Carlson RP; Hand JM; Chang J
    J Med Chem; 1990 Jan; 33(1):240-5. PubMed ID: 2104935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacology of LY290324 in the guinea-pig: an orally active, potent and selective cysteinyl leukotriene receptor antagonist.
    Boot JR; Bond A; Thomas KH; O'Brien A; Gilmore J; Todd A
    Eur J Pharmacol; 1993 Jan; 231(1):83-9. PubMed ID: 8383064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of the leukotriene antagonist verlukast: the (R)-enantiomer of MK-571.
    Jones TR; Zamboni R; Belley M; Champion E; Charette L; Ford-Hutchinson AW; Gauthier JY; Leger S; Lord A; Masson P
    Can J Physiol Pharmacol; 1991 Dec; 69(12):1847-54. PubMed ID: 1666333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a novel series of (2-quinolinylmethoxy)phenyl-containing compounds as high-affinity leukotriene receptor antagonists. 1. Initial structure-activity relationships.
    Youssefyeh RD; Magnien E; Lee TD; Chan WK; Lin CJ; Galemmo RA; Johnson WH; Tan J; Campbell HF; Huang FC
    J Med Chem; 1990 Apr; 33(4):1186-94. PubMed ID: 2157009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent airway eosinophilia after leukotriene (LT) D4 administration in the guinea pig: modulation by the LTD4 receptor antagonist, pranlukast, or an interleukin-5 monoclonal antibody.
    Underwood DC; Osborn RR; Newsholme SJ; Torphy TJ; Hay DW
    Am J Respir Crit Care Med; 1996 Oct; 154(4 Pt 1):850-7. PubMed ID: 8887574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of 3H-leukotriene D4 binding to guinea pig lung receptors by the novel leukotriene antagonist ICI 198,615.
    Aharony D; Falcone RC; Krell RD
    J Pharmacol Exp Ther; 1987 Dec; 243(3):921-6. PubMed ID: 2826761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel photoaffinity probe for the LTD4 receptor.
    Gallant M; Sawyer N; Metters KM; Zamboni RJ
    Bioorg Med Chem; 1998 Jan; 6(1):63-72. PubMed ID: 9502106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding of radiolabeled high affinity antagonist to leukotriene D4 receptor in guinea pig lung membranes: interconversion of agonist-receptor binding affinity states.
    O'Sullivan BP; Mong S
    Mol Pharmacol; 1989 Jun; 35(6):795-802. PubMed ID: 2543913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological profile of the novel, potent and selective peptide leukotriene antagonist (E)-2,2-diethyl-3'-[2-[2-(4-isopropyl)thiazolyl]ethenyl]succinanilic acid.
    Yamada N; Yamada K; Takahashi K; Nakao E; Kadowaki S; Umezu K
    Arzneimittelforschung; 1994 Jun; 44(6):749-53. PubMed ID: 8053974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and SAR of a novel, potent and structurally simple LTD4 antagonist of the quinoline class.
    von Sprecher A; Gerspacher M; Beck A; Kimmel S; Wiestner H; Anderson GP; Niederhauser U; Subramanian N; Bray MA
    Bioorg Med Chem Lett; 1998 Apr; 8(8):965-70. PubMed ID: 9871521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A series of non-quinoline cysLT1 receptor antagonists: SAR study on pyridyl analogs of Singulair.
    Guay D; Gauthier JY; Dufresne C; Jones TR; McAuliffe M; McFarlane C; Metters KM; Prasit P; Rochette C; Roy P; Sawyer N; Zamboni R
    Bioorg Med Chem Lett; 1998 Mar; 8(5):453-8. PubMed ID: 9871597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukotriene C4 induces bronchoconstriction and airway vascular hyperpermeability via the cysteinyl leukotriene receptor 2 in S-hexyl glutathione-treated guinea pigs.
    Yonetomi Y; Sekioka T; Kadode M; Kitamine T; Kamiya A; Matsumura N; Fujita M; Kawabata K
    Eur J Pharmacol; 2015 May; 754():98-104. PubMed ID: 25704617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.